I was asked to repost the following which is in response to questions about the awkward comments from BDD about the results of the Brilacidin for UC trial.
" Although absorption of Brilacidin was not observed from analysis of plasma concentrations, this was not unexpected and may indeed be a desirable attribute for a drug that acts by virtue of its local effect on inflamed mucosal surfaces within the lower GI tract. "
It means no absorption was detected in blood plasma and none was expected.
The context of the statement is important. BDD markets it products to companies seeking to enhance plasma levels and absorption to improve their biologic effects. In the BDD Brilacidin study the goal was deliver the drug to the entire colon.
IPIX previous pharmacodynamic testing has shown Brilacidin is not absorbed when taken orally or rectally. The purpose of the BDD study was to show the medication was delivered to the whole colon with the hope it will treat Ulcerative Colitis it a manner similar to its outstanding Ulcerative Proctitis study. The successful test has positive implications for treating Ulcerative Colitis in a safer and less toxic way than current treatments and has positive implications for other GI disorders including Crohn's disease.
If Brilacidin had been detected in the plasma it would not have affected the results of the BDD Brilacin study since the intravenous Brilacin in the ABSSSI study was well tolerated. Having no systemic absorption will mean the future trials will be much less likely to have systemic complications and the trials will likely have less testing of future study patients for systemic complications which should stream line future studies.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links